{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1046"},{"groupId":"OG001","value":"401"}],"units":"Participants"}],"description":"Objective 5: To describe the distribution of chemotherapy dose delays and reductions, surgery delays and cancellations, radiotherapy delays, dose reductions, and cancellations, and mortality (GCSF-related; FN-related; cancer-related; not related to GCSF, FN, or cancer; all-cause); and estimate the time-to-event for such events over the course of EP2006 treatment.\n\nTable presents number of patients with any CIN/FN-related chemotherapy disturbance by prophylaxis type.\n\nCIN: chemotherapy-induced neutropenia; FN: febrile neutropenia","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary prophylaxis for FN.","id":"OG000","title":"EP2006: Primary Prophylaxis"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for secondary prophylaxis for FN","id":"OG001","title":"EP2006: Secondary Prophylaxis"}],"paramType":"NUMBER","populationDescription":"Evaluable sample by prophylaxis type","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Number of Participants With Any CIN/FN-related Chemotherapy Disturbance by Prophylaxis Type","type":"PRIMARY","unitOfMeasure":"participants"}